articleAlzheimer s & DementiaJan 1, 2026HYBRID OA

Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts

Roche Pharma AG (Germany) · Roche (Switzerland) · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Introduction

Phospho-Tau (217P) plasma immunoassay (Roche Diagnostics) for detecting amyloid pathology.

Methods

Plasma tau phosphorylated at threonine 217 (pTau217) levels were determined in samples from cognitively impaired and unimpaired individuals from five cohorts (N = 2148) using the pTau217 plasma immunoassay. Clinical performance was evaluated against amyloid positron emission tomography.

Citation impact

4
total citations
FWCI
67.49
Percentile
99%
References
31
Too recent for citation history.

Authors

12

Topics & keywords

Keywords
  • Immunoassay
  • Predictive value
  • Amyloid (mycology)
  • Disease
  • Radioimmunoassay
No related works found for this paper.

Funding